Drug information provided by: Merative, Micromedex®
Trametinib is used alone or in combination with dabrafenib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery. It is also used together with dabrafenib to help prevent melanoma from coming back after surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations. Trametinib is also used together with dabrafenib to treat non-small cell lung cancer (NSCLC) that has spread, and anaplastic thyroid cancer (ATC) that has spread and has no satisfactory treatment options. It is only used if the NSCLC cells and ATC cells have the BRAF V600E mutation. Trametinib is also used in combination with dabrafenib to treat solid tumors that has spread, that cannot be removed by surgery, or that have gotten worse (progressed) and has no satisfactory treatment options. It is only used if the solid tumors have the BRAF V600E mutations. Trametinib is also used in combination with dabrafenib to treat low-grade glioma (LGG) in patients who require other treatments. It is only used if the brain tumor has the BRAF V600E mutations. Your doctor will use a special test to look for these mutations. Trametinib belongs to the group of medicines, called antineoplastics (cancer medicines).
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊,和我们一起进行尖端研究和医护,共同推动医学的改变。